COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
LONDON, Sept. 06, 2023 -- COMPASS Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of...
Source: marketscreener.com